Ritter Pharmaceuticals Inc (RTTR) Receives Buy Rating from Aegis
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating restated by analysts at Aegis in a report issued on Tuesday.
Several other brokerages also recently weighed in on RTTR. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 20th. Maxim Group reiterated a “buy” rating on shares of Ritter Pharmaceuticals in a research note on Tuesday, June 28th.
Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 22.99% during trading on Tuesday, reaching $2.30. The company’s stock had a trading volume of 1,344,183 shares. The stock’s market capitalization is $19.74 million. Ritter Pharmaceuticals has a 52 week low of $0.98 and a 52 week high of $2.63. The firm has a 50 day moving average of $1.57 and a 200 day moving average of $1.54.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/ritter-pharmaceuticals-inc-rttr-receives-buy-rating-from-aegis.html
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.14. Analysts expect that Ritter Pharmaceuticals will post ($1.38) EPS for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.